|

Pelvis Adaptive Radiotherapy (ART)

RECRUITINGN/ASponsored by Royal North Shore Hospital
Actively Recruiting
PhaseN/A
SponsorRoyal North Shore Hospital
Started2025-10-09
Est. completion2029-11-30
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

Pelvis Adaptive radiotherapy (ART) is a two phase study looking at using adaptive radiotherapy to help reduce toxicity for cancer patients having radiotherapy in the pelvic region. Adaptive radiotherapy is a new technology that provides the ability to account for daily changes in anatomy. Adaptive radiotherapy also provides a foundation for which radiotherapy margins might be safely reduced. Phase 1 of this study is looking to see if a radiation therapist centred adaptive workflow can be implemented. If phase 1 of this study is safe and feasible, the study will proceed to phase 2. Phase 2 of the study looks at using adaptive technology to reduce radiation treatment margins. The primary aim of this study is to see whether margin reduced treatment using adaptive radiotherapy can reduce side effects for patients with cancer in the pelvic area.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Age \> 18
2. ECOG performance status 0-2
3. Patients receiving curative or adjuvant pelvic radiation including:

   1. Prostate cancer where nodal treatment is required
   2. Prostate cancer post prostatectomy
   3. Bladder cancer
   4. Rectal cancer
   5. Anal cancer
   6. Adjuvant radiotherapy for gynaecological cancers
   7. Pelvic Lymph nodes only
4. Ability to understand and the willingness to sign an informed consent

Exclusion Criteria:

* Hip prosthesis
* Patient separation from approximate radiation centre to skin edge \> 24cm, measured on diagnostic scan

Conditions2

CancerPelvis Neoplasms

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.